Flomics new study shows a cancer predictive power of 92% and high sensitivity in the early detection of five cancer types: colorectal, lung, breast, prostate and pancreas.

Barcelona – January 31, 2025 – Flomics presented last week at the Liquid Biopsy Symposium in Santiago de Compostela, its latest study demonstrating the ability to accurately detect five major cancer types—colorectal, lung, prostate, pancreatic, and breast cancer—using cell-free RNA (cfRNA), Next-Generation Sequencing (NGS), and AI-driven bioinformatics.

The study, conducted on over 1,000 patient samples collected from eight hospitals, including Hospital Clínic de Barcelona and the Andalusian Biobank, revealed a cancer predictive power, or more technically, an area under the curve (AUC) of 92%, along with a sensitivity of 83% at 90% specificity. A particularly significant finding was the test’s ability to detect Stage I cancers with a sensitivity of 80%, reinforcing its potential as a powerful tool for early detection when treatment is most effective. These results place us at the forefront of RNA-based diagnostics, demonstrating the potential of cfRNA as a next-generation biomarker for multi-cancer screening.

Unlike conventional liquid biopsy methods that rely on circulating tumor DNA (ctDNA)—which primarily detects cancer in later stages when tumor burden is significant—our approach focuses on RNA biomarkers. RNA provides a real-time snapshot of gene expression, capturing dynamic molecular changes that occur in cancer’s earliest stages. By integrating NGS and AI-powered bioinformatics, we have developed a biomarker discovery platform capable of identifying and analyzing distinct RNA expression patterns linked to tumor presence, offering superior sensitivity for early-stage cancers.

“These results confirm that cfRNA is a powerful biomarker for early cancer detection,” said João Curado, the CEO and co-founder. “By leveraging advanced sequencing technologies and machine learning, we have developed a liquid biopsy test that is highly accurate, minimally invasive, and scalable, opening new possibilities for widespread cancer screening.”

Flomic’s study focused on five cancer types—colorectal, lung, prostate, pancreatic, and breast cancer—and demonstrated promising results across all categories. The ability to detect Stage I cancers with a sensitivity of 80% is particularly significant, as early detection dramatically improves survival rates. Flomics’ cfRNA technology offers a clear advantage over traditional methods by capturing molecular alterations missed by DNA-based approaches, making it a game-changer for preventive medicine.

With these results, we are now advancing toward clinical trials, the next critical step for regulatory approval and commercial deployment. Large-scale validation studies are being prepared in collaboration with European hospitals and research institutions to assess the test’s performance in real-world clinical settings. The company aims to bring its liquid biopsy technology to market, enabling early cancer detection through a simple blood test.

Flomics Biotech, founded in 2018 and based in Barcelona, is a leader in genomics, bioinformatics, and RNA-based diagnostics. Led by founders João Curado (CEO) and André Guedes (COO), alongside co-founders and advisors Esther Lizano, Luis Korrodi, and Roderic Guidó, the company has a team of 20 employees. By combining Next-Generation Sequencing (NGS), artificial intelligence, and RNA biomarkers, Flomics is developing the next generation of cancer screening solutions, aiming to transform early disease detection and personalized medicine.

For media inquiries, partnership opportunities, or investment discussions, please contact:

📧 info@flomics.com